These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 17480241)

  • 1. Global measures: utility in defining and measuring treatment response in dementia.
    Reisberg B
    Int Psychogeriatr; 2007 Jun; 19(3):421-56. PubMed ID: 17480241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Linking the Clinical Dementia Rating Scale-Sum of Boxes, the Clinician's Interview-Based Impression Plus Caregiver Input, and the Clinical Global Impression Scale: Evidence based on Individual Participant Data from Five Randomized Clinical Trials of Donepezil.
    Samara M; Levine SZ; Yoshida K; Goldberg Y; Cipriani A; Efthimiou O; Iwatsubo T; Leucht S; Furakawa TA
    J Alzheimers Dis; 2021; 82(3):1075-1084. PubMed ID: 34120898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal Neuropsychological Outcome in Taiwanese Alzheimer's Disease Patients Treated with Medication.
    Yang YH; Wu MN; Chou PS; Su HC; Lin SH; Sung PS
    Curr Alzheimer Res; 2018 Mar; 15(5):474-481. PubMed ID: 29032750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.
    Feldman H; Gauthier S; Hecker J; Vellas B; Xu Y; Ieni JR; Schwam EM;
    Int J Geriatr Psychiatry; 2005 Jun; 20(6):559-69. PubMed ID: 15920715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease.
    Morris JC; Cyrus PA; Orazem J; Mas J; Bieber F; Ruzicka BB; Gulanski B
    Neurology; 1998 May; 50(5):1222-30. PubMed ID: 9595967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Clinician's Interview-Based Impression of Change (Plus caregiver input) and goal attainment in two dementia drug trials: Clinical meaningfulness and the initial treatment response.
    Stanley J; Howlett SE; Dunn T; Rockwood K
    Alzheimers Dement; 2021 May; 17(5):856-865. PubMed ID: 33928754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Donepezil preserves cognition and global function in patients with severe Alzheimer disease.
    Black SE; Doody R; Li H; McRae T; Jambor KM; Xu Y; Sun Y; Perdomo CA; Richardson S
    Neurology; 2007 Jul; 69(5):459-69. PubMed ID: 17664405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Six and 18-month changes in mild to moderate Alzheimer's patients treated with acetylcholinesterase inhibitors: what can we learn for clinical outcomes of therapeutic trials?
    Cortes F; Portet F; Touchon J; Vellas B
    J Nutr Health Aging; 2007; 11(4):330-7. PubMed ID: 17653493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defining meaningful change in Alzheimer's disease trials: the donepezil experience.
    McLendon BM; Doraiswamy PM
    J Geriatr Psychiatry Neurol; 1999; 12(1):39-48. PubMed ID: 10447153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
    Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
    J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A naturalistic study of galantamine for Alzheimer's disease.
    Brodaty H; Woodward M; Boundy K; Barnes N; Allen G;
    CNS Drugs; 2006; 20(11):935-43. PubMed ID: 17044730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study.
    Aupperle PM; Koumaras B; Chen M; Rabinowicz A; Mirski D
    Curr Med Res Opin; 2004 Oct; 20(10):1605-12. PubMed ID: 15462693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical global measures of dementia. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.
    Reisberg B; Schneider L; Doody R; Anand R; Feldman H; Haraguchi H; Kumar R; Lucca U; Mangone CA; Mohr E; Morris JC; Rogers S; Sawada T
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 3():8-18. PubMed ID: 9305508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics and performance of a modified version of the ADCS-CGIC CIBIC+ for mild cognitive impairment clinical trials.
    Schneider LS; Raman R; Schmitt FA; Doody RS; Insel P; Clark CM; Morris JC; Reisberg B; Petersen RC; Ferris SH
    Alzheimer Dis Assoc Disord; 2009; 23(3):260-7. PubMed ID: 19812469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reliability study on the Japanese version of the Clinician's Interview-Based Impression of Change. Analysis of subscale items and 'clinician's impression'.
    Nakamura Y; Homma A; Kobune S; Tachibana Y; Satoh K; Takami I; Nagai S; Sakai M; Fukuta H; Matsuda H; Hashimoto H; Kusunoki T;
    Dement Geriatr Cogn Disord; 2007; 23(2):104-15. PubMed ID: 17135727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended-release physostigmine in Alzheimer disease: a multicenter, double-blind, 12-week study with dose enrichment. Physostigmine Study Group.
    van Dyck CH; Newhouse P; Falk WE; Mattes JA
    Arch Gen Psychiatry; 2000 Feb; 57(2):157-64. PubMed ID: 10665618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial.
    Doody RS; Ferris SH; Salloway S; Sun Y; Goldman R; Watkins WE; Xu Y; Murthy AK
    Neurology; 2009 May; 72(18):1555-61. PubMed ID: 19176895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term rivastigmine treatment in a routine clinical setting.
    Minthon L; Wallin AK; Eriksson S; Wattmo C; Andreasen N
    Acta Neurol Scand; 2009 Mar; 119(3):180-5. PubMed ID: 18759798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease.
    Wilkinson D; Andersen HF
    Dement Geriatr Cogn Disord; 2007; 24(2):138-45. PubMed ID: 17622761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time to Treatment Initiation in People With Alzheimer Disease: A Meta-Analysis of Randomized Controlled Trials.
    Tsoi KK; Hirai HW; Chan JY; Kwok TC
    J Am Med Dir Assoc; 2016 Jan; 17(1):24-30. PubMed ID: 26392193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.